News
Public · Published
Oppenheimer maintains BioMarin Pharmaceutical at Outperform, lowers price target to $94 from $97
Oppenheimer kept its Outperform rating on BioMarin Pharmaceutical but lowered its price target to $94 from $97, a 3.1% decrease. The new target implies 63.6% upside from the November 2 close of $57.44.
Published:
Updated:
What happened
Oppenheimer kept its Outperform rating on BioMarin Pharmaceutical but lowered its price target to $94 from $97, a 3.1% decrease. The new target implies 63.6% upside from the November 2 close of $57.44.
Confirmed
Global impact / market context
A lower target still sits far above the current share price, so Oppenheimer sees large potential gains while trimming its optimism slightly. Because other recent targets range from $60 to $122, investors face widely split views on BioMarin's value.
Analyst inference
The five most recent analyst notes show targets from $60 to $122, with several firms neutral or holding. That spread means opinion on BioMarin is divided, and Oppenheimer's small cut keeps it among the more bullish views rather than signaling a broad downgrade.
Analyst inference
What to watch
- Watch whether other firms change their BioMarin ratings or price targets after Oppenheimer's cut, since the five latest notes range from $60 to $122. Confirmed
- Track BioMarin's next company updates on revenue, costs, and product progress, because analysts may adjust targets if results differ from what they expect. Proposed
- Watch the gap between the $57.44 close and higher targets; if the share price moves toward $94, it would suggest investors are pricing in more of Oppenheimer's upside view. Analyst inference
Evidence
- Original source link unavailable